Místo: BioVendor R&D, Karasek 1767/1, Brno
Datum: 12.–13. listopadu 2024
PROGRAM 12. listopadu:
11:30–12:15 OBĚD
Kinosál
- 12:15–12:30 ÚVODNÍ INFORMACE – Hložánková, Hajdúch
- 12:30–13:00 Hajdúch (DP 11) Biomarkers and molecular diagnostics for personalized medicine
- 13:00–13:30 Vyklický/Kudová (DP 6) – Study of functional and behavioral consequences of disease-associated mutations in the NMDA receptor and potential rescue pharmacology
- 13:30–14:00 Nencka (DP 9) Novel (multi)targeted ligands of nuclear receptors for the therapy of the metabolic diseases
- 14:00–14:15 PŘESTÁVKA
- 14:15–14:45 Tichý (DP 3) Novel nucleoside analogues as potent anticancer drugs
- 14:45–15:15 Maloy Řezáčová (DP4) Theranostic applications of cancer specific carbonic anhydrases
- 15:15–15:45 Vrábel (DP 5) Development of chimeric antigen receptor modified immune cells for cancer immunotherapy
- 15:45–16:15 Martásek (DP 13) Biomedical prospecting of a life pigment: metabolic basis of inherited heme deficiency disorders
- 16:30–17:00 ZASEDÁNÍ RADY (prezenčně a/nebo online) (Decristoforo, Fusek, Hajdúch, Hauser, Martásek, Normanton, Perlík)
Místnost 21
- 13:00–14:00 ADMINISTRATIVNÍ SCHŮZKA (prezenčně a/nebo online) Projektoví manažeři konsorcia
- 16:15–16:45 Nepovinná exkurze do laboratoří společnosti BioVendor
- 18:00–20:00 VEČEŘE (Alvin restaurace – Hudcova 2, Brno-Medlánky, 621 00)
PROGRAM 13. listopadu:
Kinosál
- 09:00–9:30 Janovská (DP 12) Casein kinase inhibitors for treatment of human cancers
- 9:30–10:00 Brož (DP 1) Development of informatic solutions enabling digitalization, interpretation and management of human genome data in clinical practice
- 10:00–10:30 Macek (DP 2) Artificial intelligence, telemedicine and machine learning system for clinical applications
- 10:30–11:00 Petřík (DP 10) Targeted molecular imaging of infection and cancer disorders
- 11:00–11:30 PŘESTÁVKA/OBĚD
- 11:30–12:00 Janeba (DP7) Purine nucleoside phosphorylase inhibitors for treatment of T-cell leukemia
- 12:30–13:00 Maletínská (DP 8) Interplay between anorexigenic and orexigenic peptides in Alzheimer’s-like pathology
